Influence of hypolipaemia treatment on cadaver kidney transplant;Wplyw leczenia hipolipemicznego na czynnosc nerki przeszczepionej ze zwlok

Polskie Archiwum Medycyny Wewnetrznej

Volumn 97, Issue 2, 1997, Pages 144-156

  Pa̧czek, Leszek ^a   Bill, Marta ^a   Wyzgał, Janusz ^a   Gaciong, Zbigniew ^a   Gradowska, Liliana ^a   Juskowa, Joanna ^a   Durlik, Magdalena ^a   Lao, Mieczysław ^a  

^a Instytut Transplantologii W W

Author keywords

hypercholesterolemia; kidney transplant; lovastatin

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MEVINOLIN; PLACEBO; PREDNISONE; CHOLESTEROL; CREATININE; CYCLOSPORIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT REJECTION; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; BLOOD; CADAVER; DRUG COMBINATION; DRUG EFFECT; KIDNEY; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; ANTICHOLESTEREMIC AGENTS; AZATHIOPRINE; CADAVER; CHOLESTEROL; CHOLESTEROL, LDL; CREATININE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; KIDNEY; KIDNEY TRANSPLANTATION; LOVASTATIN; MALE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 0031062533     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Dasgupta A., Powell D., Saldana S., Doria .: Elevated lipid peroxidation products and depleted t ransferrin levels in plasma of kidney transplant recipients. Life Sci., 1990, 46, 67.
2. Castelao A.M., Grino J.M., Anders E.C. i wsp.: HMG-CoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation. Transplntat. Proc., 1993, 25, 1043.
3. Drueke T.B., Abdulmassih Z., Lacour B., Bader C., Chevalier A., Kreis M.: Atherosclerosis and lipid disorders after renal transplantation. Kidney Int., 1992, 39, Suppl. 31, 24.
4. Webb A.T., Plant M., Reaveley D.A. i wsp.: Lipid and lipoprotein(a) concentrations in renal transplant patients. Nephrol. Dial. Transplant, 1992, 7, 636.
5. Appel G.B.: Lipid abnormalities in renal disease. Kidney Int., 1991, 39, 169.
6. Grond J.: Glomerular sclerosis in nephrotic rats. Comparision of the long term effects of adriamycin and aminonucleoside. Lab. Invest., 1984, 57, 227.
7. Guijarro C., Massy Z.A., Kasiske B.L.: Clinical correlation between renal allograft failure and hyperlipidemia. Kidney Int., 1995, 48, 56.
8. Wanner C., Bartens W., Galle J.: Clinical utility of antilipidernic therapies in chronic renal allograft failure. Kidney Int., 1995, 48, 60.
9. Moore R., Thomas D., Thomas D., Morgan E. i wsp.: Abnormal lipid and lipoprotein profiles following renal transplantation. Transplnt. Proc., 1993, 25, 1060.
10. Paul L C., Hayry P., Foegh M.: Diagnostic criteria for chronic rejection/accelerated graft atherosclerosic in heart and kidney transplant: Joint proposal from the Fourth Alexis Carrel Conference on chronic Rejection and Accelerated Arterosclerosis in Transplanted Organs. Transplant. Proc., 1993, 25, 2022.
11. Can P.C.K., Robinson J.D., Yeung W.C., Cheng I.K.P., Yeung H.W.D., Tsang M.T.S.: Lovastatin in glomerulonephritis patients with hyperlipidaemia and heavy proteinuria. Nephrol. Dial. Transplant., 1992, 7, 93.
12. Keane W.F., St Peter J.V., Kasiske B.L.: Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory? Kidney Int., 1992, 42, 134.
13. Betteridge D.J., Bhatnager D., Bing R.F. i wsp.: Treatment of familial hypercholesterolemia. United Kindom lipid clinics study of provastatin and cholestyramine. Br. Med. J., 1992, 304, 1335.
14. Arnadottir M., Eriksson L.O., Germershausen J.I., Thysell H: Low-dose simvastatin is a well tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: Double-Blind, Randomized, Placebo-Controlled Study in 40 Patients. Nephron, 1994, 68, 57.
15. Kasiaske B.L., Velosa J.A., Halstenon C.E., La Belle P., Langerdorfer A., Keane W.F. - The effects of Lovastatin in hyperlipidemic patients with the nephrotic syndrome. Am. J. Kidney Dis., 1990, 15, 815.
16. Senti M., Romero R., Pedro-Botet J., Pelegri A., Nogues X., Rubies-Prat J.: Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int., 1992, 41, 1394.
17. Scully R.E., Mark E.J., Mc Neely W.F., Mc Neely B.U.: Case records of the Massachusetts General Hospital. N. Engl. J. Med., 1992, 327, 718.
18. Thomas M.E., Freestone A., Varghese Z., Persuad J.W., Moorhead J.F.: Lipoprotein(a) in patients with proteinuria. Nephrol. Dial. Transplant., 1992, 7, 597.
19. Bradford R.H., Shear C.L., Chremos A.N. i wsp.: Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results. Arch. Intern. Med., 1991, 151, 43.
20. Verbeuren T.J., Jordaens F.H., Zonnekeyn L.L., Van Hove C.E., Coene M.C., Herman A.G.: Effect of hypercholesterolemia on vascular reactivity in the rabbit. Circ. Res., 1986, 58, 552.
21. Wick G., Schett G., Amberger A., Kleindienst R., Xu Q.: Is atherosclerosis an immunologically mediated disease? Immunol. Today, 1995, 16, 27.
22. Treasure C.D., Klein J.L., Weintraub W.S. i wsp.: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients wieh coronary artery disease. N. Engl. J. Med., 1995, 332, 481.
23. Levine G.N., Keaney J.F., Vita J.A.: Cholesterol reduction in cardiovascular disease. N. Engl. J. Med., 1995, 332, 512.
24. Shikomawa H., Vanhoutte P.M.: Impared endothelium-dependent relaxation to aggregating platelets and related vascoactive substances in porcine coronary arteries in hypercholesterolemia and atherosclerosis, Circ. Res., 1989, 64, 900.
25. Bill M., Pa̧czek L., Lao M.. Wpływ lipoproteidów na czynność nerki. Pol. Arch. Med. Wewn., 1994, 91, 377.
26. Kasiske B.L.: The effect of lovastatin in hyperlipidemic patients with the nephrotic syndrome. Am. J. Kiod. Dis., 1990, 15, 8.
27. Kahan B.D.: Cyclosporine: the base of immunosuppressive therapy - present and future. Transplant. Proc., 1993, 25, 508.
28. Mol M.J.T.M., Stalenhoef A.F.H.: Adrenocortical function in patients on simvastatin. Lancet, 1990, 335, 412.
29. Mihatsch J.M., Ryffel B., Gudat F.: Morphological criteria of chronic rejection: differential diagnosis, including cyclosporine nephropathy. Transplant. Proc., 1993, 25, 2031.
30. Yilmaz S., Paavonen T., Hayry P.: Chronic rejection of rat renal allografts. Transplantation, 1992, 53, 823.
31. Dimeny E., Fellstrom B., Larsson E., Tufveson G., Lithell H.: Hyperlipoproteinemia in renal transplant recipients: Is there a linkage with chronic vascular rejection? Transplant. Proc., 1993, 25, 2065.
32. Katznelson S., Kobashigawa J.A.: Dual rols of HMG-CoA reductase inhibitors in solid organ transplantation: Lipid lowering and immunosuppression. Kidney Int., 1995, 48, 112-115.
33. Meisner N.M., Wenke K., Tiety I., Wolf S. i wsp.: Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. Transplant. Proc., 1993, 25, 2077.